Fig. 2From: Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunitiesUse of maximal dosage RAASi divided by number of times (A) hyperkalemia and (B) acute kidney injury in pre-baseline measurementsnoRAASi, no use of renin-angiotensin-aldosteron system inhibition; smRAASi, use of submaximal dosage RAASi; mRAASi, use of maximal dosage RAASiBack to article page